Dermata Therapeutics DRMA Q1 2026 Earnings Narrower Loss Surprises as PreRevenue Biotech Continues Pipeline Progress Blue Owl Capital OWL Q1 2026 Earnings EPS Surpasses Estimates Signaling Steady Momentum RELX Q2 2025 Earnings Modest EPS Beat Amid Flat Revenue Disclosure Stock Declines DECK Q1 2026 Earnings EPS Surpasses Estimates by 1337 Addus HomeCare ADUS Q1 2026 Earnings Earnings Beat Despite Soft Stock Reaction PROF Q1 2026 Earnings EPS Surprises to the Upside Stock Declines 2